Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc.

Overview
Date Founded

2009

Headquarters

999 West Broadway,Suite 720,Vancouver, BC V5Z 1K5

Type of Company

Public

Employees (Worldwide)

19

Industries

Pharmaceuticals
Retail: Drug Stores

Company Description

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Executives & Employees

Co-Founder

President, Director & Chief Executive Officer

Chief Financial Officer & Secretary

Director & Senior Vice President-Business Development

Operations Head

Vice President-Research & Development

Board of Directors

Former Chief Financial Officer at Polaris Group

Co-Founder at Organovo Holdings, Inc.

Director at La Jolla Pharmaceutical Co.

Senior Portfolio Manager at Falcon Point Capital LLC

Director & Senior Vice President-Business Development at Kintara Therapeutics, Inc.

Paths to Kintara Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Kintara Therapeutics, Inc.
Recent Transactions
Details Hidden

Kintara Therapeutics, Inc. purchases Adgero Biopharmaceuticals Holdings, Inc.

Details Hidden

Kintara Therapeutics, Inc. issued USD Common Stock and Warrants

Details Hidden

Kintara Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Legal Advisor

Advised onKintara Therapeutics, Inc. issued USD Common Stock and Warrants

Investment Advisor

Advised onKintara Therapeutics, Inc. raised money in a private placement transaction

Investment Advisor

Advised onKintara Therapeutics, Inc. raised money in a private placement transaction

Legal Advisor

Advised onKintara Therapeutics, Inc. issued USD Common Stock and Warrants

Legal Advisor

Advised onKintara Therapeutics, Inc. purchases Adgero Biopharmaceuticals Holdings, Inc.

Legal Advisor

Advised onKintara Therapeutics, Inc. purchases Del Mar Pharmaceuticals (BC) Ltd.

Advisors & Consultants
Advisor

Founder at Centrexion Therapeutics Corp.

Advisor

Member, Healthcare Equity Research Team at BMO Capital Markets Corp. (Canada)

Consultant

Co-Founder at Kintara Therapeutics, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$65.2M
Total Enterprise Value
$9.59M
Earnings Per Share
$-0.87
Revenue
$0
Net Profit
$-9.13M
EBITDA
$-8.13M
Total Debt
$0
Total Equity
$263K
TEVNet Income
-1.05x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Suppliers
Guangxi Wuzhou Zhongheng Group Co., Ltd. Pharmaceuticals | Zhangzhou, China

Guangxi Wuzhou Zhongheng Group Co., Ltd. engages in the pharmaceutical manufacturing, food production, and real estate development and management. The pharmaceutical manufacturing industry's core business includes research and development, production, sale, and service of Chinese medicines and injection products. The company was founded on April 1, 1993 and is headquartered in Zhangzhou, China.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

MacroGenics, Inc. Pharmaceuticals - Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kintara Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kintara Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Kintara Therapeutics, Inc..